Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cognate Secures Capital Raise | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Cognate Secures Capital Raise

The management buyout and capital raise will accelerate Cognate’s commercial activities for clients and prospects

By: Betsy Louda

, Contract Pharma

Cognate BioServices has completed a management buyout (“MBO”) and raised capital from a group of global investment firms including Santa Monica, Calif.-based Tennenbaum Capital Partners (“TCP”), Medivate Partners, and affiliates based in Seoul, South Korea.

 

“As an early investor in Cognate, we are very excited to expand our partnership with the company,” said Dan Worrell, managing director of TCP. “For the past two decades, TCP’s healthcare strategy has focused on investing in companies that improve healthcare by lowering costs or facilitating improved patient access and outcomes. Cognate provides critical cost-effective support to small, medium, and large biotech companies on the forefront of personalized medicine.”

 

Cognate recently opened up new manufacturing capacity to support products for both the E.U. and the U.S. in Memphis, Tennessee, and is well on its way to being able to support commercial scale production. The transaction includes significant growth capital to accelerate Cognate’s second phase of commercial expansion that began in 2015.

 

“This transaction is the culmination of years of planning and execution on the part of our highly collaborative and dedicated team with committed investors who came together to make this a reality,” according to J. Kelly Ganjei, chief executive officer of Cognate BioServices, Inc. “We are excited to have completed the second phase of our growth strategy and look forward to further demonstrating our compelling and unique value proposition to the cell therapy market.”

 

The MBO and capital raise will accelerate Cognate’s commercial activities for clients and prospects, secure the company’s future as a leading CDMO in the emerging cellular therapies space and provide a clear path to commercialization.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics